Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
IONSYS is a transdermal iontophoretic system delivering fentanyl hydrochloride, a potent opioid analgesic used for acute postoperative pain management. The iontophoresis mechanism uses a mild electric current to deliver fentanyl across intact skin on demand, providing patient-controlled analgesia without IV access. This innovative delivery technology addresses the need for non-invasive, patient-directed pain relief in hospital settings.
Product approaching loss of exclusivity with extended patent protection through 2033; team focus likely shifting toward market defense and provider relationship consolidation rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Interruptions in the Coagulationsystem in Relation With Cardiac Surgery - A Study Comparing Two Heparinization Strategies During On-pump Cardiac Surgery
An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery
Working on IONSYS offers focused expertise in specialty acute pain management and hospital-based drug delivery innovation, with exposure to unique iontophoretic technology and perioperative clinical workflows. However, limited online job listings and approaching LOE suggest this is a niche, mature product best suited for professionals seeking deep domain expertise rather than rapid career expansion.
Worked on IONSYS at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo